Excretion of Rivaroxaban in Human Breast Milk

Exclusion Criteria

• •1. Pregnant
• •2. Less than 18 years old at estimated date of delivery
• •3. Hemodynamic instability and/or concern for ongoing blood loss
• •4. Newly diagnosed deep vein thrombosis (DVT) or pulmonary embolism (PE) in the postpartum period
• •5. Abnormal maternal renal or liver function (creatinine clearance \< 30 mL/min and/or liver function tests greater than lab normal)
• •6. A contraindication to rivaroxaban: hypersensitivity to rivaroxaban; active pathological bleeding
• •7. Breastfeeding an infant admitted to neonatal intensive care unit, infant gestational age at birth \<37w0d or weighing \<2600g.
• •8. If all of the following are met: age less than 40, ambulating, body mass index (BMI) less than 30, no active history of malignancy.
• •9. If patient lacks indication for therapeutic anticoagulation in the postpartum period per the American College of Obstetricians and Gynecologists' (ACOG) practice bulletin #196